{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+label+%28none%29&page=2", "query": { "intervention": "Open label (none)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+label+%28none%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-27T10:13:54.386Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01568411", "title": "A Fixed-Sequence, Two-Period, Open-Label Drug-Drug Interaction Study to Assess the Effect of an Inhibitor of Cytochrome P450 Isoenzyme 3A4 and Permeability Glycoprotein 1 on the Pharmacokinetics of TD-1211", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "TD-1211", "type": "DRUG" }, { "name": "TD-1211+ itraconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Glycyx Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 20, "start_date": "2012-04", "completion_date": "2012-06", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-09-27T10:13:54.386Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01568411" }, { "nct_id": "NCT01331850", "title": "A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Copegus", "type": "DRUG" }, { "name": "Pegasys", "type": "DRUG" }, { "name": "RO5024048", "type": "DRUG" }, { "name": "danoprevir", "type": "DRUG" }, { "name": "ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 381, "start_date": "2011-05", "completion_date": "2013-01", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-09-27T10:13:54.386Z", "location_count": 19, "location_summary": "La Jolla, California • Long Beach, California • Sacramento, California + 15 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01331850" }, { "nct_id": "NCT05938465", "title": "Study of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an IPAA (PROF)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ileal Pouch" ], "interventions": [ { "name": "EXE-346", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Exegi Pharma, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2023-11-06", "completion_date": "2027-07-31", "has_results": false, "last_update_posted_date": "2026-05-28", "last_synced_at": "2026-09-27T10:13:54.386Z", "location_count": 8, "location_summary": "Los Angeles, California • Jacksonville, Florida • Grand Rapids, Michigan + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05938465" }, { "nct_id": "NCT03727646", "title": "Nicotinamide Riboside in LVAD Recipients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Heart Failure，Congestive", "Heart Failure New York Heart Association Class IV", "Mitochondrial Alteration" ], "interventions": [ { "name": "Nicotinamide riboside", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 5, "start_date": "2018-09-26", "completion_date": "2018-11-26", "has_results": true, "last_update_posted_date": "2024-09-20", "last_synced_at": "2026-09-27T10:13:54.386Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03727646" }, { "nct_id": "NCT01012895", "title": "Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C" ], "interventions": [ { "name": "BMS-790052", "type": "DRUG" }, { "name": "BMS-650032", "type": "DRUG" }, { "name": "Pegylated-interferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 215, "start_date": "2009-12", "completion_date": "2014-02", "has_results": false, "last_update_posted_date": "2015-10-09", "last_synced_at": "2026-09-27T10:13:54.386Z", "location_count": 10, "location_summary": "Anaheim, California • Coronado, California • San Jose, California + 7 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Coronado", "state": "California" }, { "city": "San Jose", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01012895" }, { "nct_id": "NCT02167945", "title": "A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Hepatitis C Virus (HCV) Infection Genotype 1" ], "interventions": [ { "name": "ABT-450/r/ABT-267", "type": "DRUG" }, { "name": "ABT-333", "type": "DRUG" }, { "name": "Ribavirin (RBV)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 615, "start_date": "2014-06-12", "completion_date": "2021-05-13", "has_results": true, "last_update_posted_date": "2022-07-19", "last_synced_at": "2026-09-27T10:13:54.386Z", "location_count": 48, "location_summary": "Phoenix, Arizona • Bakersfield, California • Los Angeles, California + 40 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02167945" }, { "nct_id": "NCT01628094", "title": "ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "RO5024048", "type": "DRUG" }, { "name": "RO5190591", "type": "DRUG" }, { "name": "RO5466731", "type": "DRUG" }, { "name": "ribavirin [Copegus]", "type": "DRUG" }, { "name": "ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 110, "start_date": "2012-06", "completion_date": "2013-11", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-09-27T10:13:54.386Z", "location_count": 15, "location_summary": "La Jolla, California • Englewood, Colorado • South Miami, Florida + 11 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Englewood", "state": "Colorado" }, { "city": "South Miami", "state": "Florida" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Honolulu", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT01628094" }, { "nct_id": "NCT03095391", "title": "The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of FAST PV and mGFR Technology™", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Kidney Diseases", "Renal Insufficiency, Chronic", "Acute Kidney Injury", "Urologic Diseases", "Renal Insufficiency" ], "interventions": [ { "name": "VFI", "type": "DEVICE" }, { "name": "Iohexol", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "FAST BioMedical", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 32, "start_date": "2017-06-13", "completion_date": "2017-09-20", "has_results": false, "last_update_posted_date": "2018-12-26", "last_synced_at": "2026-09-27T10:13:54.386Z", "location_count": 2, "location_summary": "Birmingham, Alabama • San Antonio, Texas", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03095391" }, { "nct_id": "NCT01889186", "title": "A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia", "17p Deletion", "Cancer of the Blood and Bone Marrow" ], "interventions": [ { "name": "ABT-199 (Main Cohort)", "type": "DRUG" }, { "name": "ABT-199 (Safety Expansion Cohort)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 158, "start_date": "2013-06-27", "completion_date": "2020-12-15", "has_results": true, "last_update_posted_date": "2021-12-16", "last_synced_at": "2026-09-27T10:13:54.386Z", "location_count": 16, "location_summary": "Tucson, Arizona • Duarte, California • La Jolla, California + 11 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01889186" }, { "nct_id": "NCT01872936", "title": "Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Infection", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Miravirsen", "type": "DRUG" }, { "name": "Telaprevir", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Santaris Pharma A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 20, "start_date": "2013-06", "completion_date": "2015-01", "has_results": false, "last_update_posted_date": "2014-11-18", "last_synced_at": "2026-09-27T10:13:54.386Z", "location_count": 2, "location_summary": "Dallas, Texas • Houston, Texas", "locations": [ { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01872936" } ] }